# Eli Lilly (LLY) stock closed notably down on April 24 following reports that its newly launched oral obesity pill, Foundayo, is trailing Novo Nordisk’s (NVO) oral Wegovy in initial uptake.

*biotech · news · 2026-04-27 · Barchart*

## Key points

- Foundayo recorded only about 3,700 prescriptions in its second week versus 18,400 for oral Wegovy.
- Lilly’s total GLP-1 prescriptions declined by 0.3% week-over-week, per IQVIA data ending April 17.
- Lilly still commands an estimated 59% share of new GLP-1 prescriptions despite Foundayo’s slow start.
- Lilly’s debt-to-EBITDA ratio is projected to fall below 1x this year, improving financial flexibility.
- LLY’s partnership with Hims & Hers expands access to Zepbound and Foundayo via LillyDirect pharmacy.

**Companies:** Eli Lilly, Novo Nordisk

[Read the full story on Barchart](https://www.barchart.com/story/news/1537355/should-you-buy-the-dip-in-eli-lilly-stock-today)

---

Canonical: https://newsio.io/n/dabdb8d8-dc8e-4e41-a13e-ca016c4c7f71/eli-lilly-lly-stock-closed-notably-down-on-april-24-following-reports-that-its-n
Summarized by Newsio from Barchart. https://newsio.io/how-it-works